ALR Technologies Inc. (ALRTF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ALRTF steht fuer ALR Technologies Inc., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 54/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026ALR Technologies Inc. (ALRTF) Gesundheitswesen & Pipeline-Uebersicht
ALR Technologies Inc. provides diabetes care solutions, including data management systems and continuous glucose monitoring (CGM) for humans and animals. Targeting healthcare providers and insurers, the company offers tools for data collection, predictive A1C, and remote monitoring, positioning itself in the evolving diabetes management market.
Investmentthese
ALR Technologies Inc. presents a focused play on the diabetes management market, targeting both human and animal health. The company's Diabetes Management System and CGM offerings address the growing need for comprehensive diabetes care solutions. A key value driver is the potential expansion of their GluCurve Pet CGM in the veterinary market, tapping into the increasing awareness and treatment of diabetes in pets. However, the company's negative P/E ratio of -1.35 and a significantly negative profit margin of -159306.4% raise concerns about its financial sustainability. Future growth hinges on successful market penetration and achieving profitability. Investors should closely monitor revenue growth, cost management, and the adoption rate of their pet-focused CGM solution.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.01B indicates a micro-cap company with high growth potential but also higher risk.
- Gross Margin of 66.2% suggests a strong ability to control production costs relative to revenue.
- Negative P/E ratio of -1.35 reflects current unprofitability, requiring careful evaluation of future earnings potential.
- Profit Margin of -159306.4% indicates significant operational challenges and the need for improved cost management.
- Beta of 2.56 suggests high volatility compared to the market, indicating a riskier investment.
Wettbewerber & Vergleichsunternehmen
Staerken
- Comprehensive Diabetes Management System.
- Unique GluCurve Pet CGM product for animal health.
- Focus on data-driven insights and remote monitoring.
- Integrated system for both human and animal diabetes care.
Schwaechen
- Negative profit margin and reliance on external funding.
- Limited market presence and brand recognition.
- Small number of employees and limited resources.
- Dependence on the success of a few key products.
Katalysatoren
- Upcoming: Potential partnerships with veterinary clinics to expand GluCurve Pet CGM sales.
- Upcoming: Development of new features and functionalities for the Diabetes Management System.
- Ongoing: Increasing awareness of diabetes in pets driving demand for GluCurve Pet CGM.
- Ongoing: Growing adoption of remote monitoring and data-driven diabetes management solutions.
Risiken
- Potential: Competition from established players in the diabetes care market.
- Potential: Regulatory changes and healthcare reforms impacting product approvals and reimbursement.
- Potential: Technological advancements that could render their products obsolete.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: Negative profit margin and challenges in achieving profitability.
Wachstumschancen
- Expansion of GluCurve Pet CGM: The market for pet diabetes care is growing, driven by increased pet ownership and awareness of pet health. ALR Technologies' GluCurve Pet CGM addresses a specific need in this market, offering veterinarians a tool for effective diabetes management in cats and dogs. Successful market penetration and partnerships with veterinary clinics could significantly boost revenue. The pet diabetes care market is projected to reach $1.5 billion by 2028.
- Adoption of Diabetes Management System: The Diabetes Management System offers a comprehensive solution for healthcare providers and insurers. Increased adoption of this system can drive revenue growth. The global diabetes management market is expected to reach $25 billion by 2027, driven by the rising prevalence of diabetes and the need for effective management tools. ALR Technologies can capitalize on this trend by demonstrating the system's effectiveness in improving patient outcomes and reducing healthcare costs.
- Partnerships with Healthcare Providers: Collaborating with healthcare providers and integrating their solutions into existing healthcare systems can expand ALR Technologies' reach. Strategic partnerships can provide access to a wider patient base and enhance the credibility of their products. The healthcare IT market is growing rapidly, with a focus on interoperability and data-driven solutions. ALR Technologies can leverage this trend by offering seamless integration with existing healthcare platforms.
- Development of Prediabetes System: The Prediabetes System, with its educational content and online community, can attract a significant user base. By providing valuable resources and support, ALR Technologies can help individuals manage their prediabetes and potentially prevent the onset of type 2 diabetes. The prediabetes market is largely untapped, presenting a significant opportunity for growth. Early intervention and lifestyle management programs are gaining traction, creating a demand for solutions like ALR Technologies' Prediabetes System.
- Geographic Expansion: While currently focused on the United States, ALR Technologies can explore opportunities to expand its market reach to other countries. The global diabetes market is vast, and international expansion can significantly increase revenue. Emerging markets with growing diabetes prevalence offer particularly attractive opportunities. However, navigating regulatory requirements and cultural differences in different countries will be crucial for successful expansion.
Chancen
- Expanding GluCurve Pet CGM sales in the growing pet health market.
- Partnering with healthcare providers and insurers.
- Developing new features and functionalities for the Diabetes Management System.
- Expanding into new geographic markets.
Risiken
- Competition from established players in the diabetes care market.
- Regulatory changes and healthcare reforms.
- Technological advancements that could render their products obsolete.
- Economic downturns that could reduce healthcare spending.
Wettbewerbsvorteile
- Specialized focus on both human and animal diabetes care.
- Proprietary Diabetes Management System with data-driven insights.
- GluCurve Pet CGM addresses a specific need in the veterinary market.
- Integrated system combining data collection, monitoring, and support.
Ueber ALRTF
ALR Technologies Inc., initially named Mo Betta Corp. before rebranding in 1998, was founded in 1987 and is headquartered in Richmond, Virginia, operating as a subsidiary of ALR Technologies SG Ltd. The company focuses on developing data-driven diabetes care solutions for both human and animal health markets. Their core product is the Diabetes Management System, a comprehensive platform that integrates data collection, predictive A1C calculations, insulin dosage suggestions, performance tracking, and remote monitoring. This system also includes diabetes test supplies. ALR Technologies also offers Continuous Glucose Monitoring (CGM) devices for real-time blood sugar readings in humans. Recognizing a gap in the animal health market, they developed GluCurve Pet CGM, specifically designed for feline and canine diabetes management, targeting veterinary professionals. Furthermore, ALR Technologies provides a Prediabetes System, featuring educational videos, mobile-friendly content, and an online community to support patients in managing prediabetes. The company's primary customer base includes healthcare providers, health insurance companies, and providers of disease and case management services, including the home care industry.
Was das Unternehmen tut
- Develops Diabetes Management System for data collection and analysis.
- Offers predictive A1C calculations and insulin dosage suggestions.
- Provides Continuous Glucose Monitoring (CGM) devices for human use.
- Manufactures GluCurve Pet CGM for diabetes management in cats and dogs.
- Creates Prediabetes System with educational videos and online community.
- Offers remote monitoring and performance tracking solutions for diabetes care.
- Provides diabetes test supplies as part of its comprehensive system.
Geschaeftsmodell
- Sells Diabetes Management System to healthcare providers and insurers.
- Generates revenue from the sale of CGM devices and related supplies.
- Offers GluCurve Pet CGM to veterinarians for animal diabetes management.
- Provides Prediabetes System subscriptions and related content.
Branchenkontext
ALR Technologies Inc. operates within the medical device industry, specifically targeting the diabetes care market. This market is driven by the increasing prevalence of diabetes globally, creating a demand for innovative monitoring and management solutions. The competitive landscape includes established players offering CGMs and diabetes management platforms. ALR Technologies differentiates itself by focusing on both human and animal health, with its GluCurve Pet CGM addressing a niche market. The industry is also influenced by technological advancements in remote monitoring and data analytics, which are integral to ALR Technologies' offerings.
Wichtige Kunden
- Healthcare providers (doctors, clinics, hospitals)
- Health insurance companies
- Veterinarians and animal health clinics
- Individuals with diabetes or prediabetes
Finanzdaten
Chart & Info
ALR Technologies Inc. (ALRTF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer ALRTF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ALRTF.
Kursziele
Wall-Street-Kurszielanalyse fuer ALRTF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ALRTF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Sidney S. Chan
CEO
Sidney S. Chan is the CEO of ALR Technologies Inc. His background includes experience in managing and growing technology-focused companies. He is responsible for the overall strategic direction and operational execution of the company. He leads a small team of 7 employees, focusing on developing and marketing diabetes care solutions for both human and animal health. His expertise lies in identifying market opportunities and driving product innovation.
Erfolgsbilanz: Under Sidney Chan's leadership, ALR Technologies Inc. has focused on expanding its product offerings in the diabetes care market, including the development of the GluCurve Pet CGM. Key milestones include securing partnerships with veterinary clinics and expanding the reach of the Diabetes Management System. However, the company's financial performance remains a challenge, with ongoing efforts to improve profitability and secure additional funding.
ALRTF OTC-Marktinformationen
The OTC Other tier, where ALR Technologies Inc. trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is distinct from exchanges like NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Companies on OTC Other may be subject to less regulatory oversight, increasing investment risk.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in ALRTF.
- Lower liquidity can make it difficult to buy or sell shares at desired prices.
- The OTC Other tier is associated with higher risk of fraud and manipulation.
- Lack of regulatory oversight compared to listed exchanges.
- Potential for delisting or trading suspension due to non-compliance.
- Verify the company's registration and legal standing.
- Review available financial statements, if any, and assess their accuracy.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and potential trading risks.
- Consult with a financial advisor before investing.
- Be aware of the risks associated with investing in OTC stocks.
- The company has been in operation since 1987.
- ALR Technologies Inc. has a specific focus on diabetes care solutions.
- The company has developed products for both human and animal health.
- The company operates as a subsidiary of ALR Technologies SG Ltd.
ALR Technologies Inc. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for ALRTF?
ALR Technologies Inc. (ALRTF) currently holds an AI score of 54/100, indicating moderate score. Key strength: Comprehensive Diabetes Management System.. Primary risk to monitor: Potential: Competition from established players in the diabetes care market.. This is not financial advice.
How frequently does ALRTF data refresh on this page?
ALRTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALRTF's recent stock price performance?
Recent price movement in ALR Technologies Inc. (ALRTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive Diabetes Management System.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ALRTF overvalued or undervalued right now?
Determining whether ALR Technologies Inc. (ALRTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ALRTF?
Before investing in ALR Technologies Inc. (ALRTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ALRTF to a portfolio?
Potential reasons to consider ALR Technologies Inc. (ALRTF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Comprehensive Diabetes Management System.. Additionally: Unique GluCurve Pet CGM product for animal health.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ALRTF?
Yes, most major brokerages offer fractional shares of ALR Technologies Inc. (ALRTF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ALRTF's earnings and financial reports?
ALR Technologies Inc. (ALRTF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ALRTF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited information available for OTC-traded companies.
- Financial data based on available information and may not be comprehensive.
- Analyst consensus and price targets may not be available due to limited coverage.